Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E54.81 EPS (ttm)1.28 Insider Own0.10% Shs Outstand1.59B Perf Week-0.51%
Market Cap111.77B Forward P/E13.98 EPS next Y5.02 Insider Trans-9.15% Shs Float1.57B Perf Month5.20%
Income2.08B PEG3.08 EPS next Q1.06 Inst Own72.50% Short Float4.92% Perf Quarter9.31%
Sales20.99B P/S5.33 EPS this Y-57.20% Inst Trans-0.07% Short Ratio8.19 Perf Half Y12.91%
Book/sh0.85 P/B82.54 EPS next Y18.40% ROA7.50% Target Price75.47 Perf Year34.58%
Cash/sh4.97 P/C14.11 EPS next 5Y17.79% ROE64.20% 52W Range49.82 - 71.60 Perf YTD9.72%
Dividend2.04 P/FCF- EPS past 5Y-17.80% ROI16.80% 52W High-2.01% Beta-
Dividend %2.91% Quick Ratio1.30 Sales past 5Y7.00% Gross Margin80.80% 52W Low40.82% ATR1.43
Employees26000 Current Ratio1.40 Sales Q/Q11.10% Oper. Margin23.80% RSI (14)55.48 Volatility2.59% 1.68%
OptionableYes Debt/Eq11.09 EPS Q/Q23.50% Profit Margin9.90% Rel Volume0.71 Prev Close70.16
ShortableYes LT Debt/Eq7.76 EarningsJul 24 BMO Payout144.20% Avg Volume9.45M Price70.16
Recom2.20 SMA201.10% SMA503.05% SMA20011.34% Volume0 Change0.00%
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Aug-12-13Initiated Argus Buy $52
May-15-13Reiterated R. F. Lafferty Buy $47.90 → $61
Apr-29-13Reiterated Barclays Equal Weight $41 → $44
Apr-15-13Reiterated Barclays Equal Weight $37 → $41
Jul-30-15 12:20PM  NBIX: Three More Data Readouts Coming in the Second Half of 2015 - Analyst Blog
11:30AM  NBIX: Three More Data Readouts Coming in the Second Half of 2015
09:30AM  The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases
08:04AM  Gilead's Hepatitis C Dominance Unchecked By AbbVie at Motley Fool
Jul-29-15 11:48AM  Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog
11:20AM  AbbVie (ABBV) Stock Price Target Raised at Deutsche Bank at TheStreet
09:40AM  Gilead (GILD) Beats on Q2 Earnings, Raises 2015 Outlook - Analyst Blog
09:04AM  Eli Lilly & Co. Earnings Analysis: By the Numbers
09:03AM  Bristol-Myers Squibb Co. Earnings Analysis: By the Numbers
Jul-28-15 06:53PM  Gilead Lifts Sales View As Hep C Drugs Top
05:12PM  Gilead higher after earnings beat
05:03PM  Express Scripts Raises Guidance as Earnings Top Views at The Wall Street Journal
04:28PM  Leon Cooperman: Allergan trying to move up
04:22PM  Gilead Sales Soar on Hepatitis Drugs at The Wall Street Journal
01:33PM  Gilead Sciences: How Will the Market React to Slowing U.S. Hep-C Sales? at Barrons.com
11:15AM  New drug approval is a win for the Bay State's horse in the hepatitis C race at bizjournals.com
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts - Press Releases
06:31AM  Merck Targets Toughest Cases for Foothold in Hepatitis C Market at Bloomberg
Jul-27-15 05:16PM  Gilead Sciences: Sure, It's Hep-C But It's Not Just Hep-C at Barrons.com
03:24PM  Is Gilead Sciences About to Make an Acquisition?
01:51PM  4 Stocks to Fight the Virus on World Hepatitis Day - Analyst Blog
11:45AM  Biogen: Buy the Stock Get the Pipeline for Free at Barrons.com
10:42AM  3 Signs That the Healthcare Stock Bubble Might Have Just Popped at Motley Fool
10:10AM  Company News for July 27, 2015 - Corporate Summary
08:21AM  Short Sellers Run For Cover From Major Pharma at 24/7 Wall St.
07:00AM  European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elotuzumab) For the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies Business Wire
06:06AM  Allergan sells generic drugs unit to Teva for $40bn at Financial Times
04:25AM  Biotech high flyers face gravity test at Financial Times
Jul-24-15 05:42PM  UPDATE 2-AbbVie, Bristol-Myers get FDA nod for hep C treatments Reuters
03:44PM  AbbVie (ABBV) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
03:20PM  AbbVie's Investments Begin Kicking In at Motley Fool
02:00PM  TECHNIVIE (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA Approval as the First and Only All-Oral, Interferon-Free Treatment for Genotype 4 Chronic Hepatitis C in the U.S. PR Newswire
01:37PM  Edited Transcript of ABBV earnings conference call or presentation 24-Jul-15 1:00pm GMT
01:20PM  Biogen's Big-Volume Plunge Marks End Of 5-Year Run
12:33PM  AbbVie's revenue miss raises concerns over Humira sales
11:44AM  Biogen Plunges On Slashed Guidance; AbbVie Q2 Mixed at Investor's Business Daily
11:33AM  AbbVie (ABBV) Stock Sliding Following Second Quarter Earnings Results at TheStreet
11:12AM  AbbVie: Beware the Biosimilars? at Barrons.com
10:39AM  AbbVie Tops Earnings, Misses on Revenues, Maintains View - Analyst Blog
09:16AM  AbbVie (ABBV) Tops 2Q Earnings but Misses Revenues - Tale of the Tape
09:10AM  Are AbbVie Earnings Enough?
09:00AM  AbbVie Inc Earnings Call scheduled for 9:00 am ET today
08:38AM  AbbVie beats 2Q profit forecasts, but sales fall short
08:26AM  AbbVie's Revenue Growth Misses Expectations at The Wall Street Journal
08:11AM  ABBVIE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:07AM  AbbVie beats 2Q profit forecasts
08:06AM  AbbVie's stock drops after sales miss expectations at MarketWatch
07:59AM  AbbVie Profit Tops Analysts Estimates as Drug Sales Rise 11% at Bloomberg
07:53AM  AbbVie Reports Second-Quarter 2015 Financial Results PR Newswire
07:07AM  Q2 2015 AbbVie Inc Earnings Release - Before Market Open
06:54AM  ISIS and drug sales 5 things to know today at Fortune
Jul-23-15 08:00PM  Stock Futures Higher, Indexes Set for Weekly Losses at Fox Business
05:48PM  Will AbbVie (ABBV) Surprise on Earnings Again in Q2? - Analyst Blog
03:37PM  4 Ways Millennials Can Buy Private Businesses at Investopedia
01:25PM  What to Expect From AbbVie Earnings
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie - Press Releases
Jul-22-15 04:50PM  Illumina Breaches Key Level On Q2 Sales Miss
04:13PM  What's Coming For Large-Cap Pharma Stocks This Earnings Season?
10:52AM  Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog
09:30AM  Zacks Industry Outlook Highlights: AbbVie, Allergan, Pfizer, Juno and Johnson & Johnson - Press Releases
08:16AM  2015s Top 6 Big Pharma Headlines Thus Far at Motley Fool
08:04AM  Will The High Cost Of Vertex's New Cystic Fibrosis Drug Push The U.S. To European Style Pricing? at Forbes
07:05AM  Coverage initiated on AbbVie by Sun Trust Rbsn Humphrey
Jul-21-15 02:52PM  Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
02:52PM  Pharma Stock Outlook - July 2015 - Industry Outlook
02:15PM  Its earnings season: Here are 9 local biotech firms that are actually making a profit at bizjournals.com
11:23AM  AbbVie: Hep-C Sales Will Be Better Than Expected at Barrons.com
Jul-20-15 06:35PM  Cramer: Johnson & Johnson needs to break up-NOW! at CNBC
04:50PM  AbbVie Neurodegenerative Disorder Drug Gets Orphan Status - Analyst Blog
Jul-18-15 12:40PM  Patients squeezed in Gilead, insurer showdown over costly hep C drugs at bizjournals.com
Jul-17-15 08:01AM  C2N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclear Palsy PR Newswire
12:37AM  Shire Deepens Push Into Biotech After AbbVie Drops Bid at The Wall Street Journal
Jul-14-15 11:25AM  Johnson & Johnson sales hit by 'biosimilar' competition at Financial Times
11:18AM  J&J Earnings Beat Views As Pharma Leads Way Again at Investor's Business Daily
10:20AM  3 Top Big Pharmaceutical Stocks With Upcoming Catalysts at 24/7 Wall St.
07:13AM  Midyear Report Card: Grading My Biotech Predictions for 2015 at Motley Fool
Jul-13-15 06:43PM  Allergan, Celgene Break Out As Other Medicals Base at Investor's Business Daily
05:03PM  Shire Deepens Push Into Biotech After Suitor Drops Bid at The Wall Street Journal
04:30PM  AbbVie (ABBV) Gains on Label Expansion of Imbruvica in EU - Analyst Blog
11:13AM  AbbVie (ABBV) Stock Climbing on Positive Analyst Note at TheStreet
08:38AM  Gilead Pills Priced at $1,000 a Day Are Found Cost-Effective at Bloomberg
08:05AM  Short Sellers Run for Cover in Big Pharma at 24/7 Wall St.
Jul-10-15 06:05PM  Don't Count Out Top Biotechs -- They Still Got Game at Investor's Business Daily
03:37PM  AbbVie (ABBV) Stock Gains After IMBRUVICA Receives EU Regulatory Approval at TheStreet
11:45AM  Gilead Sciences: Does Anyone Care About Hep-C Anymore? at Barrons.com
07:10AM  IMBRUVICA┬« (ibrutinib) Now Approved to Treat Waldenstrom's Macroglobulinemia in Europe PR Newswire
Jul-09-15 01:39PM  Gilead Sciences: Four Reasons For Optimism at Barrons.com
Jul-08-15 08:55AM  3 UBS Must-Own Large-Cap Pharmaceutical Stocks at 24/7 Wall St.
Jul-06-15 03:05PM  Are Patent Challenges Paying Off For Kyle Bass?
07:00AM  Hedge funds like these stocks for the rest of the year
Jul-02-15 08:00AM  AbbVie to Host Second-Quarter Earnings Conference Call PR Newswire
Jun-30-15 01:18PM  Citigroup Still Says Sell AbbVie at Barrons.com
Jun-29-15 02:44PM  Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent
12:00PM  Activist investors love spin-offs. Heres why you should, too at Fortune
08:07AM  Better Dividend Stock: AbbVie or Johnson & Johnson? at Motley Fool
Jun-27-15 06:32PM  WEEKEND VIDEO: Market Positives and Negatives
Jun-26-15 12:50PM  Gilead Sciences: New Scripts for Harvoni/Sovaldi Decelerating at Barrons.com
11:35AM  Is Big Pharma Advertising Getting Out of Control? at 24/7 Wall St.
Jun-24-15 05:19PM  Intrexon, Enanta Among Top Biotech New Issues at Investor's Business Daily
08:00AM  Hep C treatment succeeds in late stage study
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company's products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HURWICH THOMAS A.VP, ControllerMay 19Option Exercise22.946,200142,23274,660May 21 05:50 PM
HURWICH THOMAS A.VP, ControllerMay 19Sale66.006,200409,20068,460May 21 05:50 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Option Exercise35.88175,4776,296,115657,624Apr 30 06:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Sale64.6795,9706,206,473554,660Apr 30 06:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Sale64.928,281537,569482,147Apr 30 06:02 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 08Sale64.726,994452,652561,360Apr 30 06:01 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCMar 02Sale60.3025,0001,507,500274,116Mar 03 06:10 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 02Sale60.3012,314742,534106,954Mar 03 06:07 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 27Sale60.472,112127,706104,555Mar 03 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 27Sale60.512,074125,492123,860Mar 03 06:07 PM
HURWICH THOMAS A.VP, ControllerFeb 27Sale60.571,18571,77770,322Mar 03 06:06 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 17Sale58.7024114,147106,592Feb 19 05:51 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 09Option Exercise24.072,25054,1643,168Feb 11 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Option Exercise24.078,495204,501188,563Dec 22 05:22 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Sale68.008,495577,660180,068Dec 22 05:22 PM
HURWICH THOMAS A.VP, ControllerNov 24Sale67.811,500101,71763,211Nov 26 05:00 PM
HURWICH THOMAS A.VP, ControllerNov 06Option Exercise24.0710,000240,73171,448Nov 07 05:57 PM